Kura Oncology Inc (KURA NASDAQ) stock market data APIs
$8.1805
-0.24(-2.9%)
as of March 31, 2026
Try our APIs with
free plan!
Kura Oncology Inc Financial Data Overview
Price chart is built with
Anychart
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Prev. Close
8.1805
Open
7.943
High
8.361
Low
7.9086
52 wk Range
5.41-12.49
Market Cap
683 M
Shares Outstanding
88 330 K
Revenue
67 482 K
EPS
-0.92
Beta
0.219
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kura Oncology Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kura Oncology Inc data using free add-ons & libraries
Get Kura Oncology Inc Fundamental Data
Kura Oncology Inc Fundamental data includes:
- Net Revenue: 67 482 K
- EBITDA: -302 599 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-05
- EPS/Forecast: -0.2601
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kura Oncology Inc News
New
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers com...
Kura Oncology Q4 Earnings Call Highlights
Kura Oncology logo Key Points Komzifti launched with early commercial traction—generating $2.1 million in net product revenue in the final weeks of 2025—and achieved rapid market access (payers ...
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ...
This article first appeared on GuruFocus. Net Product Revenue: $2.1 million from KOMZIFTI sales in Q4 2025. Collaboration Revenue: $15.2 million from Kyowa Kirin partnership in Q4 2025, compared to $...
Kura Oncology GAAP EPS of -$0.92 misses by $0.18, revenue of $17.34M misses by $18.11M
* Kura Oncology press release [https://seekingalpha.com/pr/20425187-kura-oncology-reports-fourth-quarter-and-full-year-2025-financial-results] (KURA [https://seekingalpha.com/symbol/KURA]): Q4 GAAP ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
